📽New Video YouTube Video Outlining Recent Acquisition🎞I love how Bradley Dottin founder of Dyscovry Science's puts it as a "cocktail".
Silo Wellness’s (CSE:SILO,OTCQB:SILFF)acquisition of Toronto-based biotech firm Dyscovry Science provides an opportunity for the company to expand into the pharmaceutical space and biotech research, said Bradley Dottin, founder and president of Dyscovry Science.
Dyscovry has been focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition called irritable bowel syndrome, a common disorder in the gastrointestinal tract affecting up to 15 percent of the world’s population. Silo Wellness is a psychedelic wellness company focused on researching psilocybin and developing psychedelic wellness facilities in jurisdictions with no legal barriers.
“So what we bring here is threefold," Dottin said. "We have a biosynthetic pathway, which allows us to work towards the production of psilocybin. And we also have a therapeutic angle with an indication specifically for irritable bowel syndrome coming alongside.
<br />